About goodrx holdings inc. - GDRX
GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. It offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.
GDRX At a Glance
GoodRx Holdings, Inc.
2701 Olympic Boulevard
Santa Monica, California 90404
| Phone | 1-855-268-2822 | Revenue | 796.85M | |
| Industry | Medical/Nursing Services | Net Income | 30.44M | |
| Sector | Health Services | 2025 Sales Growth | 0.572% | |
| Fiscal Year-end | 12 / 2026 | Employees | 697 | |
| View SEC Filings |
GDRX Valuation
| P/E Current | 23.916 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 31.77 |
| Price to Sales Ratio | 1.214 |
| Price to Book Ratio | 1.50 |
| Price to Cash Flow Ratio | 5.76 |
| Enterprise Value to EBITDA | 6.496 |
| Enterprise Value to Sales | 1.567 |
| Total Debt to Enterprise Value | 0.435 |
GDRX Efficiency
| Revenue/Employee | 1,143,261.119 |
| Income Per Employee | 43,671.449 |
| Receivables Turnover | 3.127 |
| Total Asset Turnover | 0.568 |
GDRX Liquidity
| Current Ratio | 2.614 |
| Quick Ratio | 2.614 |
| Cash Ratio | 1.064 |
GDRX Profitability
| Gross Margin | 82.089 |
| Operating Margin | 13.424 |
| Pretax Margin | 7.095 |
| Net Margin | 3.82 |
| Return on Assets | 2.171 |
| Return on Equity | 4.54 |
| Return on Total Capital | 2.626 |
| Return on Invested Capital | 2.529 |
GDRX Capital Structure
| Total Debt to Total Equity | 88.08 |
| Total Debt to Total Capital | 46.831 |
| Total Debt to Total Assets | 38.327 |
| Long-Term Debt to Equity | 86.498 |
| Long-Term Debt to Total Capital | 45.99 |
Goodrx Holdings Inc. in the News
Novo Nordisk to sell weight-loss drug for $499 to eligible customers
Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.